FontStyle: Roboto Light and Medium 17 pt

Font Color: 231f20

Hotspot tests can miss genetic alterations associated with therapies in up to

25% of lung cancer patients.1

25% of lung tissue biopsies are found Quantity-Not-Sufficient (QNS)

for diagnosis.2

See how Guardant360 can help

patients avoid repeat biopsies and

get the right treatment

Color: 333e48 for copy below

PATIENT

74 year old female

DIAGNOSIS

Lung adenocarcinoma

GENOMIC PROFILING

Tissue QNS

03/2015 (Web color for dates only: 346094) and 14 pt

Tissue biopsy

Insufficient for genotyping

03/2015 (Web color for dates only: 346094) and 14 pt

Avoiding repeat biopsy,

Guardant360 identified

*EGFR* L858R, an

actionable mutation

04/2015 (Web color for dates only: 346094) and 14 pt

First-line treatment

initiated with Erlotinib

06/2015 (Web color for dates only: 346094) and 14 pt

CT scan demonstrated partial

response and *EGFR* L858R

not detected in ctDNA

21 point Roboto Light black:

New clinical validation

study compares Guardant360

sequencing to tissue

14 Point for link:

Read more

Point size: 17 point black

The deadline to submit abstracts

to AACR is December 1, 2015 and

ASCO is February 2, 2016.

Roboto Regular 14 point White reverse

Abstract Information: AACR ASCO

Color: 333e48 and 21 point

Guardant Health team

walks for Lung Cancer

Last month Guardant Health employees turned out by the dozen for a 5K run and walk supporting the Bonnie J. Addario Lung Cancer Foundation. Overall, the event brought in more than $200,000.

Color: 009bde

Click here to learn more

about the foundation’s work.

Andy, I will send another file for the bottom area of copy on newsletter.